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OBJECTIVES Our aim was to study whether an insertion/deletion (I/D) polymorphism in the a2B-
adrenoceptor gene is associated with the risk for cardiovascular diseases.
BACKGROUND a2-adrenoceptors mediate contraction of vascular smooth muscle and induce coronary
vasoconstriction in humans. The a2-adrenoceptor subtype B mediates vasoconstriction in
mice. A variant of the human a2B-adrenoceptor gene that encodes a D of three residues in
an intracellular acidic motif has been shown to confer decreased receptor desensitization. This
receptor variant could, therefore, be involved in diseases associated with enhanced vasocon-
striction.
METHODS This study was part of a prospective population-based study investigating risk factors for
cardiovascular diseases in a cohort of middle-aged men from eastern Finland. Nine hundred
twelve men aged 46 to 64 years were followed for an average time of 4.5 years.
RESULTS In this study population, 192 men (21%) had the D/D genotype; 256 (28%) had the I/I
genotype, and 464 (51%) had a heterozygous genotype. In a Cox model adjusting for other
coronary risk factors, men with the D/D genotype had 2.2 times (95% confidence interval: 1.1
to 4.4, p 5 0.02) the risk to experience an acute coronary event (n 5 15 for D/D, 10 for I/I
and 12 for I/D) compared with men carrying either of the other two genotypes. The
a2B-adrenoceptor genotype was not associated with hypertension in this study population.
CONCLUSIONS The D/D genotype of the a2B-adrenoceptor is a novel genetic risk factor for acute coronary
events, but not for hypertension. (J Am Coll Cardiol 2001;37:1516–22) © 2001 by the
American College of Cardiology
Three a2-adrenoceptor (a2-AR) subtypes have been iden-
tified to date and have been named a2A-AR, a2B-AR and
a2C-AR. a2-AR subtype-selective drugs are not available.
This complicates the investigation of the physiologic role
and therapeutic potential of the a2-AR subtypes. A major
step forward in discovering the roles of the different a2-AR
subtypes in regulation of the cardiovascular system was
recently achieved with strains of genetically engineered mice
deficient in either a2A-AR or a2B-AR or a2C-AR (1–3).
The results of these studies suggest that the a2C-AR
subtype does not affect either blood pressure or vasocon-
striction, that the a2A-AR mediates the central hypotensive
effects of clonidine-like a2-AR agonists and that the
a2B-AR mediates peripheral vasoconstriction induced by
this class of drugs (4). The tissue distribution of the a2-AR
subtypes is not yet known in detail, especially in humans,
and the extent of a2B-AR expression in vascular tissues is
unknown. While some studies have failed to detect a2B-AR
expression in the aorta of experimental animals (5,6), it has
been shown that a2B-ARs are expressed in rat vascular
smooth muscle cells, where the receptors are localized
diffusely along the plasma membrane (7), in human (8) and
rat kidney (9), and possibly in central pathways of the
autonomic nervous system (10). A recent in vivo study in
humans demonstrated that activation of a2-ARs reduces
coronary blood flow in both normal and atherosclerotic
arteries (11).
A variant form of the human a2B-AR gene was recently
identified (12). The variant allele encodes a receptor protein
with a deletion (D) of three glutamate residues in an acidic
stretch of 18 amino acids (of which 15 are glutamates)
located in the third intracellular loop of the receptor
polypeptide. This long acidic stretch is a unique feature in
the primary structure of a2B-AR in comparison with
a2A-AR and a2C-AR. An amino acid sequence alignment
of a2B-AR polypeptides of different mammals reveals that
the acidic stretch is conserved in mammalian a2B-ARs and
that the acidic stretch is long in humans in comparison with
other species. This suggests that the motif is important for
the functionality of the receptor and that the short form (D)
probably represents the ancestral form and the long form
(insertion [I]) could well represent a more recent allelic
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variant in humans. Removal of negatively charged amino
acids from a synthetic peptide, part of the third intracellular
loop of the a2A-AR, implied that they are necessary for
receptor phosphorylation by b-adrenoceptor kinase (13).
Jewell-Motz and Liggett (14) studied in vitro the func-
tions of this acidic stretch using site-directed mutagenesis to
delete, as well as to substitute, 16 amino acids of the stretch.
The wild-type a2B-AR underwent approximately 52%
functional desensitization in transfected cells while agonist-
promoted desensitization was ablated in both mutated
receptors. The mutated receptors underwent agonist-
promoted phosphorylation at levels of only 45% to 50%
relative to the wild-type a2B-AR. Using similar methods,
the same group recently showed that the deletion variant,
targeted by the current study, is sufficient to impair agonist-
promoted receptor desensitization to a similar extent as D of
the entire acidic stretch (15). Thus, the natural polymor-
phism determines the susceptibility of the receptor to
modulation by a key mechanism of dynamic regulation.
Based on the coronary vasoconstrictive property of a2-
ARs in humans, the peripheral vasoconstrictive property of
the a2B-AR subtype in mice and the significance of this
acidic region for the desensitization of the receptor, we
hypothesized that the naturally occurring D variant confers
reduced receptor desensitization and, therefore, increased
vasoconstriction in humans. This property could be associ-
ated with cardiovascular pathologies, such as acute coronary
events and hypertension. To test this hypothesis, we carried
out a prospective study in 912 middle-aged Finnish men.
METHODS
Study population. This study was carried out as part of the
Kuopio Ischemic Heart Disease Risk Factor Study (KIHD),
which is an ongoing prospective population-based study
designed to investigate risk factors for cardiovascular dis-
eases and related outcomes in men from eastern Finland
(16). This area is known for its homogenous population (17)
and high coronary morbidity and mortality rates (18). The
KIHD study protocol was approved by the Research Ethics
Committee of the University of Kuopio. The present study
population is the second cohort of the KIHD study,
examined in 1989 to 1993. The subject recruitment is
detailed in Figure 1. This study, thus, contains data from a
representative population sample of 912 men, aged 46 (n 5
222), 52 (n 5 230), 58 (n 5 250) or 64 (n 5 210) years at
the beginning of the follow-up. All subjects gave their
written informed consent. The average time of follow-up
was 4.5 years (range 1 to 7.6 years). The follow-up was
started from the day of drawing blood for DNA extraction
and was ended (truncated) at the end of 1996.
Assessment of acute coronary events. To assess the oc-
currence of acute coronary events, diagnostic information
was collected from the Finnish hospital discharge registry,
which covers all inpatient admissions into all hospitals and
district health centers in Finland. These data were classified
by an internist (T.A.L.) using diagnostic criteria that are
based on the protocol of the World Health Organization
(WHO) MONICA project (http://www.ktl.fi/publications/
monica/manual/index.htm). In short, an acute coronary
event was defined either as a definite acute myocardial
infarction (AMI) or a possible AMI, based on electrocar-
diogram (ECG), clinical, laboratory or autopsy findings or
as an episode of acute chest pain of .20 min without
diagnostic ECG or enzyme findings, but requiring hospi-
talization (prolonged chest pain).
Only first events were used in the analysis; a subject was
excluded from further analysis when an acute coronary event
had occurred.
Measurement of covariates and blood specimens. The
collection of blood specimens, the measurement of serum
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
AR 5 adrenergic receptor
BMI 5 body mass index
BP 5 blood pressure
CHD 5 coronary heart disease




KIHD 5 Kuopio Ischemic Heart Disease
Risk Factor study
LDL 5 low density lipoprotein
PCR 5 polymerase chain reaction
RR 5 relative risk
WHO 5 World Health Organization
Figure 1. Subject recruitment flowchart: the Kuopio Ischemic Heart
Disease Risk Factor (KIHD) study. AMI 5 acute myocardial infarction;
AR 5 adrenergic receptor; D 5 deletion; I 5 insertion.
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lipids and lipoproteins, plasma fibrinogen, blood glucose and
serum insulin have been previously described (19,20). Detailed
descriptions of the following have also been published earlier:
blood pressure measurements (21), examination protocol (16),
assessment method of medical history, use of medication,
smoking, consumption of food and alcohol, intake of nutrients
(19) and exercise test protocol (22).
Coronary heart disease (CHD) in the family was deter-
mined when either a parent or a sibling of a subject had a
history of CHD, as assessed by a questionnaire. A history of
CHD was defined as a history of AMI or angina pectoris
(23) or at least weekly use of nitroglycerin for chest pain.
Treatment for hypertension was assessed by a self-
administered questionnaire where the subject was asked to
report the regular use of any drug prescribed by a physician
at the time of examination. The subject was defined as
taking antihypertensive medication if he reported regular
use of an antihypertensive drug as classified by WHO’s
Anatomical Therapeutic Chemical (ATC) code (24). Di-
agnosis of hypertension was made when a subject had a
systolic blood pressure (BP) $165 mm Hg or diastolic BP
$95 or was treated for hypertension.
DNA extraction and analysis. DNA for genotyping was
extracted from peripheral blood using standard methods.
The a2B-AR I/D genotypes were determined by separating
polymerase chain reaction (PCR) amplified DNA frag-
ments with electrophoresis. Based on the nature of the I/D
variant, identification of the long and short alleles was
achieved by their different electrophoretic migration rates
due to their 9 base pair (bp) size difference. A few samples of
each genotype were sequenced to confirm the identification of
the genotype based on the electrophoresis.
The region of interest was amplified using a sense primer
59-AGG-GTG-TTT-GTG-GGG-CAT-CT-39 and an
antisense primer 59-CAA-GCT-GAG-GCC-GGA-
GAC-ACT-39 (Oligold, Eurogentec, Seraing, Belgium),
yielding a product size of 112 bp for the long allele (I) and
103 bp for the short allele (D). Polymerase chain reaction
amplification was conducted in a 10 mL volume containing
approximately 100 ng genomic DNA, 13 buffer G (Invitro-
gen, San Diego, California), 0.8 mM dNTPs, 0.3 mM of
each primer and 0.25 U of AmpliTaq DNA polymerase
(Perkin Elmer Cetus, Norwalk, Connecticut). Samples were
amplified with a GeneAmp PCR System 9600 (Perkin
Elmer Cetus). After initial denaturation at 94°C for 2 min,
the samples were amplified over 35 cycles. Polymerase chain
reaction amplification conditions were 96°C (40 s), 69°C
(30 s) and 72°C (30 s) followed by final extension at 72°C
for 6 min.
After amplification, samples were loaded onto 4% Meta-
Phor agarose gel (FMC BioProducts, Rockland, Maine)
with ethidium bromide staining. The different alleles were
identified based on their different electrophoretic migration
rates (Fig. 2).
To prevent observer bias, the investigators who surveyed
and examined the subjects were blinded to the subjects’
genotype, and the investigator who performed the genotyp-
ing was blinded to the clinical data.
The genotyping result of each subject was I/I (which is a
homozygous form of the published a2B-AR sequence [25]),
D/D (which is a homozygous form of the recently discov-
ered variant) or I/D.
Statistical analysis. Statistical computations were per-
formed with SPSS/Win version 8.0.1 software (SPSS Inc.,
Chicago, Illinois). Chi-square tests were used for analysis of
discrete variables (two-sided Fisher exact significance test
was used in 2 3 2 tables). One-way analysis of variance or
Student t test was used for continuous variables (presented
as mean 6 SD). To assess the possible association of the
a2-AR I/D polymorphism with the risk for an acute
coronary event, univariate Cox regression analysis was
performed, first for all three genotype groups and next for
comparison of the D/D genotype with the two others
combined, now assuming a recessive mode of inheritance.
Multivariate Cox regression analysis was performed to
assess the impact of possible confounding and modifying
factors on the observed association. Variables that were
associated (p , 0.10 in the above analyses) with the a2B-AR
I/D genotype were entered into a multivariate Cox regres-
sion model. The same procedure was performed for all
variables that were previously identified as risk factors for
CHD in this study population. The variables identified in
these two models were entered together with all established
major risk factors for CHD (26) into a new multivariate
Cox regression model.
RESULTS
Results from the entire cohort. Of the 912 subjects, 192
(21%) had the D/D genotype; 256 (28%) had the I/I
genotype, and 464 (51%) were heterozygous. This genotype
distribution is in Hardy-Weinberg equilibrium (p 5 0.46).
Thirty-seven acute coronary events occurred during the
follow-up time: 15 in the D/D genotype group (7.8%), 12 in
the I/D group (2.6%) and 10 in the I/I group (3.9%). Of
these 37 acute coronary events, 18 were classified as definite
AMI, 12 as possible AMI and 7 as prolonged chest pain
(Table 1).
Figure 2. Electrophoretic separation of the polymerase chain reaction
products. The insertion (I) and deletion (D) alleles were identified based on
their different migration rates. bp 5 base pair.
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Using a univariate Cox regression model, the risk for an
acute coronary event differed significantly between the three
genotype groups (p 5 0.017). The D/D genotype group had
a 3.0 times increased risk for an acute coronary event in
comparison with the I/D group (95% confidence interval
[CI] 5 1.4 to 6.5, p 5 0.004) and a nonsignificantly
increased risk of 1.9 relative to the I/I genotype group (95%
CI 5 0.8 to 4.1, p 5 0.128). The relative risk of the I/D
genotype group was not significantly different from that of
the I/I group (relative risk [RR] 5 0.6, 95% CI 5 0.3 to 1.4,
p 5 0.251). We also applied the same analysis only to events
classified as definite or possible AMI, excluding the pro-
longed chest pain category of the FINMONICA coronary
event classification (30 events). In this analysis (overall: p 5
0.002), the RR of the D/D group was significantly different
from the I/D (RR 5 4.1, 95% CI 5 1.8 to 9.3, p 5 0.0009)
and the I/I groups (RR 5 3.1, 95% CI 5 1.2 to 8.0, p 5
0.02). The risk ratio between the I/D and I/I groups was not
significantly different from unity (RR 5 0.8, 95% CI 5 0.3
to 2.1, p 5 0.6). These results suggest that the D allele
confers its effect on the risk for coronary events in a recessive
mode of inheritance.
Analysis using a model of recessive inheritance. In a
univariate Cox regression model, the D/D genotype was
associated with an acute coronary event risk of 2.5 (95%
CI 5 1.3 to 4.8, p 5 0.006) relative to the I/D and the I/I
groups combined. A Kaplan-Meier survival function of
event-free time (Fig. 3) illustrates the consistently increased
incidence of acute coronary events in the D/D group
compared with the combined I/D and I/I group. Applying
the same Cox regression analysis only to the definite or
possible AMI events, excluding the prolonged chest pain
category, revealed a risk of 3.7 (95% CI 5 1.8 to 7.5, p 5
0.0006) for the D/D group relative to the two others
combined. When the Cox analysis for all events (including
prolonged chest pain) was performed on the data from a
subpopulation of men with no history of CHD at study
outset (n 5 787; 25 events), an RR of 2.3 (95% CI 5 1.0 to
5.2, p 5 0.04) for an acute coronary event was found for the
D/D genotype group.
Multivariate analysis. Eighty-seven variables were tested
for their association with the a2B-AR I/D polymorphism to
explore possible confounding factors. The genotype groups
were not different in terms of known major risk factors for
CHD (26). Three variables were significantly different (p ,
0.05) between the three genotype groups. Thus, the D/D
group had a higher incidence of acute coronary events; of
them, more were in the “definite AMI” category according
to the FINMONICA classification. This group also had a
significantly higher mean level of blood hemoglobin. When
compared with the I/D and the I/I genotype groups
combined, the D/D genotype group had more common
ischemic findings in exercise ECG and a lower mean
Figure 3. Event-free Kaplan-Meier survival function for acute coronary
events. D 5 deletion; I 5 insertion.
Table 1. All Variables That Were Significantly Different Between the Genotype Groups
D/D I/D I/I I/D 1 I/I p (df 5 2) p (df 5 1)
All subjects (n 5 912)
Men at risk 192 464 256 720
Acute coronary events* 15 (7.8) 12 (2.6) 10 (3.9) 22 (3.1) 0.008 0.006
FINMONICA classification† 10; 5; 0 3; 6; 3 5; 1; 4 8; 7; 7 0.033‡ 0.04§
Ischemic findings in exercise test* 57 (30) 108 (23) 52 (20) 160 (22) 0.065 0.036
Mean blood hemoglobin\ 149.0 6 10.2 146.6 6 9.1 147.1 6 10.2 146.8 6 9.5 0.016 0.005
Mean 4-day dietary cholesterol intake¶ 412 6 163 444 6 164 433 6 165 440 6 164 0.071 0.033
No history of CHD at study outset (n 5 787)
Men at risk 170 395 222 617
Acute coronary events* 10 (5.9) 7 (1.8) 8 (3.6) 15 (2.4) 0.035 0.044
FINMONICA classification 8; 2; 0 0; 6; 1 5; 1; 2 5; 7; 3 0.006‡ 0.058§
Ischemic findings in exercise test* 45 (27) 60 (15) 36 (16) 96 (16) 0.004 0.002
Mean blood hemoglobin\ 149.4 6 10.1 146.4 6 8.9 147.1 6 10.1 146.7 6 9.4 0.003 0.001
Mean 4-day dietary cholesterol intake¶ 410 6 162 452 6 166 432 6 164 445 6 165 0.17 0.13
*Number (and percent of men at risk); †events in each event category: definite AMI; possible AMI; prolonged chest pain; ‡df 5 4; §df 5 2; \g/l; ¶mg. p values are calculated
for analysis of all three genotype groups (df 5 2) and for analysis of the D/D genotype group vs. the I/D and the I/I genotype groups combined (df 5 1).
CHD 5 coronary heart disease; D 5 deletion; df 5 degree of freedom; I 5 insertion.
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four-day dietary cholesterol intake (Table 1). In addition,
the a2B-AR I/D polymorphism was nonsignificantly (0.1 .
p . 0.05) associated with body mass index (BMI) (I/I .
D/D . I/D). The same associations were also found in the
subpopulation of men with no history of CHD. Thus, the
blood hemoglobin concentration, ischemic findings in ex-
ercise ECG, the mean four-day dietary cholesterol intake
and BMI were introduced into a Cox regression model
together with the variables that were previously described as
AMI risk factors in this study population. Of these vari-
ables, hypertension, low density lipoprotein (LDL) choles-
terol level and family history of CHD were identified by this
model as independent AMI risk factors.
In a Cox proportional hazards’ model adjusting for age,
serum LDL and high density lipoprotein cholesterol levels,
smoking, hypertension, BMI, diabetes and family history of
CHD, the RR associated with the D/D genotype was 2.2
(95% CI 5 1.1 to 4.4, p 5 0.02). The RR was 3.2 (95%
CI 5 1.5 to 6.7, p 5 0.002) when the analysis was
performed using only the definite and the probable AMI
events (n 5 30). When only men with no history of CHD
were included in the analysis, the adjusted RR associated
with the D/D genotype was 2.2 (95% CI 5 1.0 to 5.0, p 5
0.06) (Table 2).
a2B-AR genotype and hypertension. No significant asso-
ciations were observed between hypertension-related vari-
ables and the a2B-AR I/D genotypes. Two hundred and six
men were treated for hypertension at study outset; of them,
44 (21%) had the D/D genotype; 98 (48%) had the I/D
genotype, and 64 (31%) had the I/I genotype. This geno-
type distribution is not different from a random distribution
(p 5 0.49). There were no significant differences between
the genotypes in terms of either systolic or diastolic BP
(Table 3).
DISCUSSION
This prospective cohort study indicates that there is a strong
association between a D variant of the a2B-AR gene and an
increased risk for acute coronary events in Finnish middle-
aged men. Men with the D/D genotype had 2.5 times the
risk of experiencing an acute coronary event as compared
with men with the I/D and the I/I genotypes. This genetic
risk was independent of other major risk factors for CHD
(adjusted RR 5 2.2, 95% CI 5 1.1 to 4.4, p 5 0.02). The
risk for an acute coronary event was significantly different
between the three genotype groups. This difference was
further strengthened by limiting the analysis to events
classified as definite or possible AMI, excluding the cases of
prolonged chest pain requiring hospitalization. This differ-
ence in risks suggested a recessive model of inheritance for
the genetic risk conferred by the D allele. This study also
Table 2. Relative Risk for an Acute Coronary Event: Results of Multivariate Cox Regression Models
Risk Factor
All Men; AMI and Prolonged
Chest Pain
All Men; Definite and
Probable AMI
Men Free of Prior CHD; AMI
and Prolonged Chest Pain
RR 95% CI p Value RR 95% CI p Value RR 95% CI p Value
D/D vs. I/D and I/I combined 2.22 1.13–4.36 0.020 3.20 1.53–6.70 0.002 2.19 0.96–4.99 0.06
Age 1.09 1.03–1.15 0.003 1.09 1.02–1.17 0.008 1.06 0.99–1.13 0.08
LDL cholesterol 1.65 1.12–2.43 0.011 1.55 1.00–2.42 0.052 1.94 1.21–3.10 0.006
HDL cholesterol 0.52 0.16–1.75 0.292 0.49 0.13–1.86 0.292 0.83 0.20–3.43 0.800
Cigarette smoking 1.04 1.01–1.07 0.010 1.05 1.02–1.08 0.003 1.04 1.00–1.08 0.032
Hypertension 2.28 1.08–4.82 0.031 2.48 1.05–5.88 0.039 2.35 0.98–5.62 0.055
BMI 0.97 0.87–1.07 0.518 0.97 0.86–1.08 0.580 0.96 0.85–1.09 0.537
Diabetes 1.32 0.39–4.49 0.660 1.73 0.50–6.02 0.391 1.38 0.30–6.38 0.677
Family history of CHD 3.48 1.57–7.70 0.002 3.82 1.54–9.50 0.004 2.60 1.06–6.35 0.036
Results are presented for the entire study population (n 5 912) analyzed using the event definition based on three categories (37 events) when only the definite and the probable
AMI event categories were used, excluding the prolonged chest pain category (30 events), and for a subpopulation of men with no prior coronary heart disease (CHD) analyzed
using all three event categories (n 5 787, 25 events). The adjustment was performed for known major risk factors for CHD and the strongest risk factors identified in the current
study.
AMI 5 acute myocardial infarction; BMI 5 body mass index; CI 5 confidence interval; D 5 deletion; HDL 5 high density lipoprotein; I 5 insertion; LDL 5 low density
lipoprotein; RR 5 relative risk.
Table 3. Prevalence of Treatment for Hypertension and the Level of Blood Pressure in the a2B-
AR Genotypes
D/D I/D I/I All
p
(df 5 2)
Treated* 44 (21) 98 (48) 64 (31) 206 (100) 0.49
Blood pressure—subjects not treated for hypertension†
Systolic BP 136 6 16 (148) 134 6 16 (366) 134 6 16 (192) 134 6 16 (706) 0.53
Diastolic BP 89 6 11 (148) 88 6 10 (366) 89 6 9 (192) 88 6 10 (706) 0.25
Blood pressure—all subjects
Systolic BP 138 6 17 (192) 135 6 16 (464) 136 6 17 (256) 136 6 17 (912) 0.18
Diastolic BP 90 6 10 (192) 89 6 10 (464) 90 6 9 (256) 89 6 10 (912) 0.12
*Numbers are n (percent of all treated subjects); †mm Hg; numbers are mean 6 SD (n).
BP 5 blood pressure; D 5 deletion; df 5 degree of freedom; I 5 insertion.
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suggests that this polymorphism is not associated with
hypertension in Finnish men. We do not presently know
whether similar associations exist in other populations, but
we have preliminary information that the I/D allele fre-
quencies are quite similar in other European populations as
well.
Our hypothesis that the D variant of the a2B-AR gene
confers increased vasoconstriction is based on two premises:
the impaired desensitization associated with the D variant
and the role of the a2B-AR in vasoconstriction. The
functional significance of this I/D polymorphism of the
a2B-AR gene has recently been investigated in an in vitro
cell culture model. The results indicated that the D variant
conferred clearly impaired receptor desensitization proper-
ties under prolonged agonist activation compared with the I
form (15). The assumption that the a2B-AR is critically
involved in the regulation of vasoconstriction cannot be
directly tested in in vivo studies in humans, as subtype-
selective a2B-AR drugs are not available. Studies in gene-
targeted mice have clearly documented a prominent role for
the a2B-AR in vasoconstriction (1). Despite that the per-
ception of the a2B-AR subtype as an important mediator of
vasoconstriction is based on studies in mice only, the
similarity of the blood pressure responses to a2-AR agonists
in humans and laboratory rodents (1) suggests that the
a2B-AR, rather than the a2A-AR or the a2C-AR, is the
subtype that mediates vasoconstriction in humans also.
Augmentation in the constrictive properties of coronary
arteries may be involved in the increased incidence of acute
coronary events indirectly as the cause for intimal tearing
leading to AMI or directly as in a coronary artery spasm
(27,28). Increased vasoconstriction could lead to the ob-
served higher prevalence of ischemic findings and incidence
of coronary events in the D/D group by at least two
additional mechanisms: 1) decreased coronary blood flow
due to increased vasoconstriction of small coronary arteries,
and 2) increased total peripheral resistance that leads to
increase cardiac work load and increased oxygen demand.
The a2B-AR I/D genotype emerges in this study as an
independent risk factor for acute coronary events, but the
statistical association is not proof of causality. To examine
the possibility that the D allele is a genetic marker for acute
coronary events rather than a causative factor, we searched
the literature for known genetic risk factors for CHD and
their chromosomal localization. All other known genetic
markers of CHD risk are located on different chromosomes
than the a2B-AR gene (chromosome 2), favoring a causal
relationship. Nevertheless, since the mechanism suggested
for explaining this association has not been rigorously
proven in vivo, it remains a real possibility that this I/D
polymorphism is a genetic marker, rather than a causative
factor, for acute coronary events.
a2B-AR polymorphism and hypertension. There was no
evidence for an association between the a2B-AR D variant
and hypertension in our study. A similar result was reported
by Baldwin et al. (29) in a study of 155 hypertensive sibling
pairs. Therefore, it is possible that this variant truly has no
effect on systemic BP or that its effect on BP is too small to
be detected using the approaches employed by Baldwin et
al. (29) or by us.
Study limitations. The lack of a proven in vivo mechanism
is a weakness of this study. The suggested mechanism of
increased vasoconstriction mediated by a2B-AR due to
decreased desensitization is based on the role of a2B-AR in
peripheral vasoconstriction in transgenic mice (1) and an in
vitro desensitization study on the D variant expressed in
transfected cells (15). We hypothesized that deletion of
three amino acids in this stretch can cause the same effect in
humans in vivo. The large differences between the studies’
conditions—the species and tissue differences and the na-
ture of the outcome measures—weaken the plausibility of
the suggested mechanism and necessitate further studies on
the physiological effects of this D variant on the human
cardiovascular system.
Conclusions. Taken together, the known biological prop-
erties of the a2B-AR in mice, the impaired desensitization
properties of the D variant in vitro and the employed
prospective study design suggest that the D variant of the
a2B-AR gene is a causal risk factor for acute coronary events
in Finnish men. To confirm the causality, the association of
the D/D genotype with acute coronary events needs to be
tested in other well-designed genetic epidemiological stud-
ies, and its physiological in vivo effects need to be identified.
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